Matthew Kamil, MD
Endocrinology, Diabetes & Metabolism · Concord, NHNPI 1427016567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,528 of the $163,055 with a category attached, or 83.1%. 27 manufacturers reported payments, led by Lilly USA, LLC at 33.4% of the total. Reporting peaked in 2019 at $53,950 and has fallen 98.0% since, to $1,065 in 2025. Among endocrinology, diabetes & metabolism clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $234.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$54K
- AstraZeneca$44K
- Novo Nordisk$27K
- Boehringer Ingelheim$18K
- Johnson & Johnson$15K
- Corcept Therapeutics$1K
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$135,52883%
- Travel & lodging$11,5117%
- Food & beverage$12,9958%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 158 | $54,408 |
| AstraZeneca | 262 | $44,426 |
| Novo Nordisk | 68 | $26,974 |
| Boehringer Ingelheim | 61 | $18,496 |
| Johnson & Johnson | 46 | $15,131 |
| Corcept Therapeutics | 9 | $1,315 |
| Amgen | 17 | $334 |
| Abbott | 7 | $264 |
| AbbVie | 12 | $216 |
| Radius Health, Inc. | 9 | $194 |
| Merck | 10 | $193 |
| Sanofi-aventis U.S. LLC | 8 | $187 |
| Tandem Diabetes Care, Inc. | 4 | $163 |
| Mannkind Corporation | 1 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Senseonics, Incorporated | 2 | $77 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 3 | $59 |
| Medtronic | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Lifescan, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $26 |
| Clarus Therapeutics Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,055 in reported general payments places this provider in the 95th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
See all endocrinology, diabetes & metabolism providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,096 | $1,551,368 |
| KorlymMifepristone | 12 | $726,119 |
| JardianceEmpagliflozin | 495 | $602,769 |
| OzempicSemaglutide | 263 | $448,363 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 195 | $310,604 |
| Tresiba Flextouch U-200Insulin Degludec | 197 | $236,241 |
| TrulicityDulaglutide | 155 | $235,879 |
| FarxigaDapagliflozin Propanediol | 186 | $233,944 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 132 | $188,541 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 70 | $105,305 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 33 | $75,979 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $71,643 |
| ForteoTeriparatide | 14 | $63,216 |
| InvokanaCanagliflozin | 48 | $61,868 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 78 | $59,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Lyumjev, Baqsimi | $54,408 | $1,908,5851,361 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $26,974 | $769,100490 claims |
| Corcept TherapeuticsKorlym | $1,315 | $726,11912 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $18,496 | $647,676527 claims |
| AstraZenecaFarxiga | $44,426 | $233,944186 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $187 | $188,541132 claims |
| Johnson & JohnsonInvokana | $15,131 | $61,86848 claims |
| MerckJanuvia | $193 | $35,34627 claims |
| Radius Health, Inc.Tymlos | $194 | $28,73411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
Other endocrinology, diabetes & metabolism in Concord
- Kevin AraoConcord$542
- Michael DavidsonDover$204K
- Dylan ThomasDover$17K
- Paul LabinsonNashua$5K
- Sreenija SuryadevaraLebanon$4K
- Harpreet RaiLebanon$2K
- Jhansi MaradanaDover$1K
- Adriana Maldonado-BremManchester$800
- Mini MahataStratham$558
- John PorembaNashua$493
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.